Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

 
• By Mandy Jackson

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

Medicine stops disease domino effect
Biogen/Eisai's Aduhelm is first to market but other anti-amyloid drugs, like donanemab, will feel the NCD decision impact • Source: Alamy

More from Drug Pricing

More from Scrip